Akt inhibition synergizes with polycomb repressive complex 2 inhibition in the treatment of multiple myeloma

Polycomb repressive complex 2 (PRC2) components, EZH2 and its homolog EZH1, and PI3K/Akt signaling pathway are focal points as therapeutic targets for multiple myeloma. However, the exact crosstalk between their downstream targets remains unclear. We herein elucidated some epigenetic interactions fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Rizk, Mohamed, Rizq, Ola, Oshima, Motohiko, Nakajima‐Takagi, Yaeko, Koide, Shuhei, Saraya, Atsunori, Isshiki, Yusuke, Chiba, Tetsuhiro, Yamazaki, Satoshi, Ma, Anqi, Jin, Jian, Iwama, Atsushi, Mimura, Naoya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6890440/
https://www.ncbi.nlm.nih.gov/pubmed/31571328
http://dx.doi.org/10.1111/cas.14207

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6890440/
https://www.ncbi.nlm.nih.gov/pubmed/31571328
http://dx.doi.org/10.1111/cas.14207

Ejemplares similares